Cargando…

The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy

OBJECTIVES: The goal of this study was to investigate whether an operation can offer survival benefits for patients with a second primary non-small-cell lung cancer (NSCLC) after a lobectomy for a first primary NSCLC and to analyse the characteristics affecting the survival of those patients. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lei-Lei, Wang, Rang-Rang, Qian, Jia-Yi, Liu, Yu’e, Ma, Shang-Shang, Li, Ming-Jun, Xie, Long-Yan, Li, Zhi-Xin, Li, Kun, Sheng, Bing-Yong, Ding, Jun-Rong, Xie, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521628/
https://www.ncbi.nlm.nih.gov/pubmed/37713470
http://dx.doi.org/10.1093/icvts/ivad155
_version_ 1785110171628863488
author Wu, Lei-Lei
Wang, Rang-Rang
Qian, Jia-Yi
Liu, Yu’e
Ma, Shang-Shang
Li, Ming-Jun
Xie, Long-Yan
Li, Zhi-Xin
Li, Kun
Sheng, Bing-Yong
Ding, Jun-Rong
Xie, Dong
author_facet Wu, Lei-Lei
Wang, Rang-Rang
Qian, Jia-Yi
Liu, Yu’e
Ma, Shang-Shang
Li, Ming-Jun
Xie, Long-Yan
Li, Zhi-Xin
Li, Kun
Sheng, Bing-Yong
Ding, Jun-Rong
Xie, Dong
author_sort Wu, Lei-Lei
collection PubMed
description OBJECTIVES: The goal of this study was to investigate whether an operation can offer survival benefits for patients with a second primary non-small-cell lung cancer (NSCLC) after a lobectomy for a first primary NSCLC and to analyse the characteristics affecting the survival of those patients. METHODS: We performed survival analyses of patients with a second primary NSCLC based on the Surveillance, Epidemiology and End Results program and used propensity score matching to reduce the potential bias and analyse the data. In addition, the primary observational end point was overall survival (OS), and the secondary observational end point was histologic migration. RESULTS: The data from 944 patients were used to perform the main analysis. A total of 36.2% of patients experienced a shift in tumour histologic type between 2 diagnoses of primary NSCLC, and this shift significantly affected OS (P = 0.0065). The median survival time in patients with surgical resection and those without an operation was 52.0 months versus 33.0 months, respectively. Patients with surgical resection at the secondary diagnosis had better survival than those without surgery (5-year OS rate: 48.0% vs 34.0%, P < 0.001). In addition, compared with a pneumonectomy and a sublobar resection, a lobectomy was the optimal surgical procedure for patients diagnosed with a second primary NSCLC after adjusting for other confounders (adjusted hazard ratio: 0.68, P < 0.01). However, in the subgroup analysis, lobar and sublobar resections could provide similar survival benefits for patients with tumour size ≤20 mm (P = 0.5). CONCLUSIONS: The operation, especially a lobectomy, can prolong OS in patients with a second primary NSCLC. Besides, sublobar resection can be performed in selected patients with tumour size ≤20 mm. Moreover, histologic migration may impact the survival of those patients with a secondary primary NSCLC.
format Online
Article
Text
id pubmed-10521628
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105216282023-09-27 The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy Wu, Lei-Lei Wang, Rang-Rang Qian, Jia-Yi Liu, Yu’e Ma, Shang-Shang Li, Ming-Jun Xie, Long-Yan Li, Zhi-Xin Li, Kun Sheng, Bing-Yong Ding, Jun-Rong Xie, Dong Interdiscip Cardiovasc Thorac Surg Thoracic Oncology OBJECTIVES: The goal of this study was to investigate whether an operation can offer survival benefits for patients with a second primary non-small-cell lung cancer (NSCLC) after a lobectomy for a first primary NSCLC and to analyse the characteristics affecting the survival of those patients. METHODS: We performed survival analyses of patients with a second primary NSCLC based on the Surveillance, Epidemiology and End Results program and used propensity score matching to reduce the potential bias and analyse the data. In addition, the primary observational end point was overall survival (OS), and the secondary observational end point was histologic migration. RESULTS: The data from 944 patients were used to perform the main analysis. A total of 36.2% of patients experienced a shift in tumour histologic type between 2 diagnoses of primary NSCLC, and this shift significantly affected OS (P = 0.0065). The median survival time in patients with surgical resection and those without an operation was 52.0 months versus 33.0 months, respectively. Patients with surgical resection at the secondary diagnosis had better survival than those without surgery (5-year OS rate: 48.0% vs 34.0%, P < 0.001). In addition, compared with a pneumonectomy and a sublobar resection, a lobectomy was the optimal surgical procedure for patients diagnosed with a second primary NSCLC after adjusting for other confounders (adjusted hazard ratio: 0.68, P < 0.01). However, in the subgroup analysis, lobar and sublobar resections could provide similar survival benefits for patients with tumour size ≤20 mm (P = 0.5). CONCLUSIONS: The operation, especially a lobectomy, can prolong OS in patients with a second primary NSCLC. Besides, sublobar resection can be performed in selected patients with tumour size ≤20 mm. Moreover, histologic migration may impact the survival of those patients with a secondary primary NSCLC. Oxford University Press 2023-09-15 /pmc/articles/PMC10521628/ /pubmed/37713470 http://dx.doi.org/10.1093/icvts/ivad155 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Thoracic Oncology
Wu, Lei-Lei
Wang, Rang-Rang
Qian, Jia-Yi
Liu, Yu’e
Ma, Shang-Shang
Li, Ming-Jun
Xie, Long-Yan
Li, Zhi-Xin
Li, Kun
Sheng, Bing-Yong
Ding, Jun-Rong
Xie, Dong
The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
title The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
title_full The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
title_fullStr The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
title_full_unstemmed The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
title_short The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
title_sort clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
topic Thoracic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521628/
https://www.ncbi.nlm.nih.gov/pubmed/37713470
http://dx.doi.org/10.1093/icvts/ivad155
work_keys_str_mv AT wuleilei theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT wangrangrang theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT qianjiayi theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT liuyue theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT mashangshang theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT limingjun theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT xielongyan theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT lizhixin theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT likun theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT shengbingyong theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT dingjunrong theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT xiedong theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT wuleilei clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT wangrangrang clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT qianjiayi clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT liuyue clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT mashangshang clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT limingjun clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT xielongyan clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT lizhixin clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT likun clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT shengbingyong clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT dingjunrong clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy
AT xiedong clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy